We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ampio Pharmaceuticals

News List

Ampio Begins Phase Trial of Inhaled Ampion for COVID-19 Patients with Respiratory Distress americanpharmaceuticalreview
November 02, 2020
Ampio Pharmaceuticals has begun recruiting and enrolling patients in a Phase I multi-center, randomized, controlled trial for a total of 40 patients that will assess the safety and efficacy of inhaled Ampion added to the standard of care (SOC) for ...
FDA Grants IND, Approves Trial Protocol of Inhaled Ampion for COVID-19 americanpharmaceuticalreview
September 27, 2020
Ampio Pharmaceuticals announces the receipt of an Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA), allowing the Company to proceed with clinical trials for the use of Ampion as an inhalation therapy for respiratory ...
Ampio Preparing Expanded Access FDA Protocol to Study Ampion for Severe COVID-19 ARDS americanpharmaceuticalreview
March 26, 2020
Ampio Pharmaceuticals is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 (COVID-19) induced Acute Respiratory Distress Syndrome (ARDS).